Option chain shows key data for Sumitomo Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sumitomo Pharma.

Sumitomo Pharma (OTC:DNPUF) Stock, Option Chain

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Photo by Pavel Ignatov on Shutterstock

Earnings

News

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

BABA

TSLA

MYOV

DNPUF

WYNN

YUMC

TWTR

The major U.S. index futures point to a higher open on Monday following the strong gains posted by all three major averages last week.

US Stocks Could Continue Last Week&#39;s Momentum As Nasdaq, S&amp;P 500 Futures Surge Ahead Of Tech-Heavy Earnings Week — Tesla, Twitter, Chinese Companies In Focus

Photo by Myriam Zilles on Unsplash

Biotech

General

Myovant Sciences, Inc. (NYSE: MYOV) announced late Sunday a deal to be acquired by Japanese pharmaceutical company Sumitomo Pharma Co., Ltd&#39;s (OTC: DNPUF) unit Sumitovant Biopharma.

Myovant Agrees To Be Acquired By Sumitomo Pharma Unit In $1.7B Deal As Japanese Company Sweetens Bid

Penny Stocks

Health Care

Contracts

NBRV

SMDPY

Nabriva Therapeutics Stock Gains On Positive Lefamulin Data In CABP Patients In China

DAI NIPPON PHARM ORD by DAI Nippon Pharmaceutical

Sumitomo Pharma Co Ltd

Sumitomo Pharma

Comments

Sumitomo Pharma

Sumitomo Pharma (DNPUF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga